Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.90
CELG's Cash to Debt is ranked higher than
59% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. CELG: 0.90 )
CELG' s 10-Year Cash to Debt Range
Min: 0.03   Max: No Debt
Current: 0.9

Equity to Asset 0.31
CELG's Equity to Asset is ranked higher than
55% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. CELG: 0.31 )
CELG' s 10-Year Equity to Asset Range
Min: -0.68   Max: 0.92
Current: 0.31

-0.68
0.92
Interest Coverage 19.75
CELG's Interest Coverage is ranked higher than
56% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CELG: 19.75 )
CELG' s 10-Year Interest Coverage Range
Min: 4.47   Max: 428.04
Current: 19.75

4.47
428.04
F-Score: 7
Z-Score: 5.96
M-Score: -2.68
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 27.05
CELG's Operating margin (%) is ranked higher than
94% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. CELG: 27.05 )
CELG' s 10-Year Operating margin (%) Range
Min: -2309.09   Max: 31.71
Current: 27.05

-2309.09
31.71
Net-margin (%) 20.82
CELG's Net-margin (%) is ranked higher than
93% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. CELG: 20.82 )
CELG' s 10-Year Net-margin (%) Range
Min: -2309.09   Max: 28.88
Current: 20.82

-2309.09
28.88
ROE (%) 30.19
CELG's ROE (%) is ranked higher than
97% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. CELG: 30.19 )
CELG' s 10-Year ROE (%) Range
Min: -164.94   Max: 25.94
Current: 30.19

-164.94
25.94
ROA (%) 9.39
CELG's ROA (%) is ranked higher than
93% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. CELG: 9.39 )
CELG' s 10-Year ROA (%) Range
Min: -210.92   Max: 14.41
Current: 9.39

-210.92
14.41
ROC (Joel Greenblatt) (%) 158.53
CELG's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. CELG: 158.53 )
CELG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1408.7   Max: 210.38
Current: 158.53

-1408.7
210.38
Revenue Growth (%) 25.10
CELG's Revenue Growth (%) is ranked higher than
91% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CELG: 25.10 )
CELG' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 166.8
Current: 25.1

0
166.8
EBITDA Growth (%) 21.90
CELG's EBITDA Growth (%) is ranked higher than
92% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. CELG: 21.90 )
CELG' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 75.6
Current: 21.9

0
75.6
EPS Growth (%) 21.40
CELG's EPS Growth (%) is ranked higher than
91% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. CELG: 21.40 )
CELG' s 10-Year EPS Growth (%) Range
Min: -63.2   Max: 118.1
Current: 21.4

-63.2
118.1
» CELG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

CELG Guru Trades in Q3 2013

John Keeley 1,320 sh (New)
Louis Moore Bacon 20,000 sh (New)
Steven Cohen 83,110 sh (+368.52%)
Jeremy Grantham 137,612 sh (+34.27%)
Mario Gabelli 10,470 sh (+29.5%)
Ronald Muhlenkamp 143,305 sh (+0.29%)
Chuck Royce Sold Out
John Hussman Sold Out
RS Investment Management 47,720 sh (-2.21%)
Pioneer Investments 1,540,161 sh (-4.58%)
Jim Simons 1,667,600 sh (-25.53%)
Paul Tudor Jones 4,100 sh (-38.81%)
Ken Fisher 2,490 sh (-44.85%)
» More
Q4 2013

CELG Guru Trades in Q4 2013

Ray Dalio 6,700 sh (New)
Chuck Royce 900 sh (New)
Mario Gabelli 11,170 sh (+6.69%)
Ronald Muhlenkamp 147,425 sh (+2.87%)
John Keeley 1,320 sh (unchged)
Pioneer Investments 1,537,450 sh (-0.18%)
RS Investment Management 42,330 sh (-11.3%)
Ken Fisher 2,206 sh (-11.41%)
Jim Simons 1,405,469 sh (-15.72%)
Jeremy Grantham 86,922 sh (-36.84%)
Paul Tudor Jones 2,402 sh (-41.41%)
Louis Moore Bacon 5,000 sh (-75%)
Steven Cohen 18,867 sh (-77.3%)
» More
Q1 2014

CELG Guru Trades in Q1 2014

John Burbank 1,670 sh (New)
Ken Fisher 37,321 sh (+1591.8%)
Ray Dalio 71,200 sh (+962.69%)
Louis Moore Bacon 42,614 sh (+752.28%)
Steven Cohen 71,089 sh (+276.79%)
Paul Tudor Jones 6,686 sh (+178.35%)
Jim Simons 1,606,830 sh (+14.33%)
Ronald Muhlenkamp 149,325 sh (+1.29%)
Pioneer Investments 1,552,050 sh (+0.95%)
John Keeley Sold Out
Mario Gabelli 10,770 sh (-3.58%)
RS Investment Management 40,572 sh (-4.15%)
Chuck Royce 600 sh (-33.33%)
Jeremy Grantham 34,100 sh (-60.77%)
» More
Q2 2014

CELG Guru Trades in Q2 2014

Joel Greenblatt 63,980 sh (New)
George Soros 688,000 sh (New)
Stanley Druckenmiller 276,000 sh (New)
Ken Fisher 131,064 sh (+75.59%)
Mario Gabelli 23,120 sh (+7.34%)
Steven Cohen 204,200 sh (unchged)
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
John Burbank Sold Out
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
Pioneer Investments 3,052,643 sh (-1.66%)
RS Investment Management 75,104 sh (-7.44%)
Jeremy Grantham 50,000 sh (-26.69%)
Ronald Muhlenkamp 144,140 sh (-51.74%)
Jim Simons 495,900 sh (-84.57%)
» More
» Details

Insider Trades

Latest Guru Trades with CELG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ronald Muhlenkamp 2014-06-30 Reduce -51.74%1.91%$68.45 - $86.8 $ 92.3522%144140
George Soros 2014-06-30 New Buy0.45%$68.45 - $86.8 $ 92.3522%688000
Ray Dalio 2014-06-30 Sold Out 0.08%$68.45 - $86.8 $ 92.3522%0
Joel Greenblatt 2014-06-30 New Buy0.07%$68.45 - $86.8 $ 92.3522%63980
John Burbank 2014-06-30 Sold Out 0.01%$68.45 - $86.8 $ 92.3522%0
Ray Dalio 2014-03-31 Add 962.69%0.07%$69.65 - $85.97 $ 92.3516%142400
John Burbank 2014-03-31 New Buy0.01%$69.65 - $85.97 $ 92.3516%3340
John Keeley 2014-03-31 Sold Out $69.65 - $85.97 $ 92.3516%0
Ronald Muhlenkamp 2013-12-31 Add 2.87%0.12%$72.25 - $85.39 $ 92.3517%294850
Ray Dalio 2013-12-31 New Buy0.01%$72.25 - $85.39 $ 92.3517%13400
John Hussman 2013-09-30 Sold Out 0.31%$60.13 - $77.31 $ 92.3532%0
John Keeley 2013-09-30 New Buy$60.13 - $77.31 $ 92.3532%2640
Mario Gabelli 2013-09-30 Add 29.5%$60.13 - $77.31 $ 92.3532%20940
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 53.30
CELG's P/E(ttm) is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 53.30 )
CELG' s 10-Year P/E(ttm) Range
Min: 17.91   Max: 618.59
Current: 53.3

17.91
618.59
P/B 15.24
CELG's P/B is ranked higher than
62% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. CELG: 15.24 )
CELG' s 10-Year P/B Range
Min: 4.02   Max: 23.45
Current: 15.24

4.02
23.45
P/S 11.14
CELG's P/S is ranked higher than
78% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. CELG: 11.14 )
CELG' s 10-Year P/S Range
Min: 5.37   Max: 28.35
Current: 11.14

5.37
28.35
PFCF 37.85
CELG's PFCF is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 37.85 )
CELG' s 10-Year PFCF Range
Min: 14.96   Max: 2925.5
Current: 37.85

14.96
2925.5
EV-to-EBIT 39.20
CELG's EV-to-EBIT is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 39.20 )
CELG' s 10-Year EV-to-EBIT Range
Min: 15.1   Max: 820.6
Current: 39.2

15.1
820.6
PEG 2.41
CELG's PEG is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 2.41 )
CELG' s 10-Year PEG Range
Min: 1.38   Max: 2.29
Current: 2.41

1.38
2.29
Shiller P/E 70.13
CELG's Shiller P/E is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 70.13 )
CELG' s 10-Year Shiller P/E Range
Min: 56.57   Max: 2211
Current: 70.13

56.57
2211
Current Ratio 5.44
CELG's Current Ratio is ranked higher than
78% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. CELG: 5.44 )
CELG' s 10-Year Current Ratio Range
Min: 1.35   Max: 44.53
Current: 5.44

1.35
44.53
Quick Ratio 5.19
CELG's Quick Ratio is ranked higher than
79% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. CELG: 5.19 )
CELG' s 10-Year Quick Ratio Range
Min: 1.13   Max: 44.15
Current: 5.19

1.13
44.15

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 3.12
CELG's Price/DCF (Projected) is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 3.12 )
CELG' s 10-Year Price/DCF (Projected) Range
Min: 1.66   Max: 123.97
Current: 3.12

1.66
123.97
Price/Median PS Value 1.02
CELG's Price/Median PS Value is ranked higher than
85% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. CELG: 1.02 )
CELG' s 10-Year Price/Median PS Value Range
Min: 0.48   Max: 9.3
Current: 1.02

0.48
9.3
Price/Peter Lynch Fair Value 2.22
CELG's Price/Peter Lynch Fair Value is ranked higher than
97% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CELG: 2.22 )
CELG' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.36   Max: 5.1
Current: 2.22

0.36
5.1
Earnings Yield (Greenblatt) 2.60
CELG's Earnings Yield (Greenblatt) is ranked higher than
66% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. CELG: 2.60 )
CELG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 6.6
Current: 2.6

0.1
6.6
Forward Rate of Return (Yacktman) 25.29
CELG's Forward Rate of Return (Yacktman) is ranked higher than
97% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. CELG: 25.29 )
CELG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -0.9   Max: 34.2
Current: 25.29

-0.9
34.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CMXHY » details
Traded in other countries:CG3.Germany
Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. In 1986, it was spun off from Celanese Corporation and, in July 1987, completed an initial public offering. Its initial operations focused on the research and development of chemical and biotreatment processes for the chemical and pharmaceutical industries. The company is dedicated to research and development designed to bring new therapies to market and is involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmunity and placental cell, including stem and progenitor cell, research. The drug and cell therapies Celgene develops are designed to treat life-threatening diseases or chronic debilitating conditions where patients are poorly served by current therapies. In October 2010, it acquired Abraxis Bioscience Inc., or Abraxis, a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients treatments for cancer and other critical illnesses. The acquisition of Abraxis accelerates its strategy to become a global leader in oncology and added ABRAXANE, which is based on Abraxis' proprietary tumor-targeting platform known as nab technology, to its portfolio of cancer products. n January 2010, it acquired Gloucester Pharmaceuticals, Inc., or Gloucester, a privately held pharmaceutical company which developed new therapies that address unmet medical needs in the treatment of hematological cancers, including cutaneous T-cell lymphoma, or CTCL, peripheral T-cell lymphoma, or PTCL, and other hematological malignancies. Gloucester added ISTODAX to its product portfolio and advanced its leadership position in the development of disease-altering therapies through innovative approaches for patients with rare and debilitating blood cancers. Celgene is investing in a range of innovative therapeutic programs that are investigating ways to treat and manage chronic diseases by targeting the disease source through multiple mechanisms of action. Celgene's commercial stage products include REVLIMID, THALOMID, VIDAZA, ALKERAN and FOCALIN. FOCALIN is sold exclusively to Novartis Pharma AG, or Novartis. Celgene also derives revenues from a licensing agreement with Novartis, which entitles the firm to royalties on FOCALIN XR and the entire RITALIN family of drugs, and sales of bio-therapeutic products and services through its Cellular Therapeutics subsidiary. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in ongoing research and development
» More Articles for CELG

Headlines

Articles On GuruFocus.com
Ken Fisher's Top Increases of the First Quarter Apr 22 2014 
David Winters' 2013 Letter to Wintergreen Fund Shareholders Mar 05 2014 
You Can No Longer Ignore Biotech Feb 07 2014 
Trying to Beat the Market Is a Fool’s Errand Oct 17 2013 
Insiders Are Buying Idera Pharmaceuticals Sep 19 2013 
comment on CELG Mar 20 2013 
Growth Stocks: There Is a Lot of Value in this Market Part 2 Sep 27 2012 
High frowth cheap in Jun 30 2012 
52-Week High Companies: CVS, TSM, PM, ROST, CELG Feb 27 2012 
52-Week High Companies: CELG, MON, ECL, SBUX, NWSA Jan 16 2012 

More From Our Partners
Stock Market News for September 16, 2014 - Market News Sep 16 2014 - ZACKS

More From Other Websites
Why Cramer wants to buy AGIO Sep 16 2014
Cramer: Keep eye on APPL, FB, & more Sep 15 2014
Biotech still place to be: Pro Sep 15 2014
Nasdaq Falls Hard, But Apple Resilient On iPhone Orders Sep 15 2014
Stocks Stumble At Open; Mobileye Rebounds Sep 15 2014
Today's Thorns, Roses and All Time Highs in the Market... Sep 11 2014
Stocks Bounce As Nasdaq, S&P 500 Close With Small Gains Sep 11 2014
Stocks Show Modest Losses; Biotechs Pressured Again Sep 11 2014
Short Sellers Remain Vigilant Against Biotechs Sep 11 2014
Celgene Corporation Easing Back After Run To New All-Time Highs - Is It Buyable Yet? Sep 11 2014
Stock Trading Ideas for 9/10/12 Sep 10 2014
SunTrust Robinson Humphrey Starts Coverage on 5 Top Biotech Stocks Sep 08 2014
Celgene's Revlimid Impresses in Phase III NDMM Study Sep 05 2014
[video] 3 Biotech picks: Gilead, Biogen & Celgene Sep 05 2014
Celgene: Good Data But What About the Patent Challenges? Sep 04 2014
Phase III FIRST™ (MM-020/IFM 07-01) Trial of REVLIMID® (lenalidomide) Plus Dexamethasone in Newly... Sep 04 2014
Three Stocks Top-Performing Funds Like: Facebook Baidu Gilead Sep 03 2014
Cramer: Twitter and other 'irresistible' stocks Sep 02 2014
Today's Thorns, Roses and All Time Highs in the Markets... Sep 02 2014
VentiRx Pharmaceuticals Provides Corporate and Clinical Update Sep 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK